ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT00654732

Public ClinicalTrials.gov record NCT00654732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 25, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2)

Study identification

NCT ID
NCT00654732
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
M.D. Anderson Cancer Center
Other
Enrollment
58 participants

Conditions and interventions

Interventions

  • Bleomycin Drug
  • Dacarbazine Drug
  • Doxorubicin Hydrochloride Drug
  • Rituximab Biological
  • Vinblastine Drug

Drug · Biological

Eligibility (public fields only)

Age range
17 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 18, 2008
Primary completion
Sep 4, 2018
Completion
Sep 4, 2018
Last update posted
Feb 27, 2020

2008 – 2018

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136
Rush University Medical Center Chicago Illinois 60612
Memorial Sloan Kettering Cancer Center New York New York 10065
M D Anderson Cancer Center Houston Texas 77030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00654732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 27, 2020 · Synced Apr 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00654732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →